Discounted Cash Flow (DCF) Analysis Unlevered

Verona Pharma plc (VRNA)

$12.61

+0.05 (+0.40%)
All numbers are in Millions, Currency in USD
Stock DCF: - | 12.61 | undervalue

Operating Data

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue ----------
Revenue (%)
EBITDA ----------
EBITDA (%)
EBIT ----------
EBIT (%)
Depreciation ----------
Depreciation (%)

Balance Sheet Data

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Total Cash ----------
Total Cash (%)
Account Receivables ----------
Account Receivables (%)
Inventories ----------
Inventories (%)
Accounts Payable ----------
Accounts Payable (%)
Capital Expenditure ----------
Capital Expenditure (%)

Weighted Average Cost Of Capital

Share price $ 12.61
Beta 0.536
Diluted Shares Outstanding 59.15
Cost of Debt
Tax Rate 0.03
After-tax Cost of Debt 5.85%
Risk-Free Rate
Market Risk Premium
Cost of Equity 6.223
Total Debt 5.81
Total Equity 745.86
Total Capital 751.67
Debt Weighting 0.77
Equity Weighting 99.23
Wacc

Build Up Free Cash

Year
A/P
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Actual
2022
Projected
2023
Projected
2024
Projected
2025
Projected
2026
Projected
Revenue ----------
EBITDA ----------
EBIT ----------
Tax Rate 8.97%17.54%18.53%-0.22%0.03%8.97%8.97%8.97%8.97%8.97%
EBIAT ----------
Depreciation ----------
Accounts Receivable ----------
Inventories ----------
Accounts Payable ----------
Capital Expenditure --0.34--0.08-0.01-----
UFCF ----------
WACC
PV UFCF -----
SUM PV UFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 6.22
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -142.57
Equity Value -
Shares Outstanding 59.15
Equity Value Per Share -